# LuCarbo (NCT06303713)

> LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: lutetium lu 177 vipivotide tetraxetan plus carboplatin
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06303713
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Prostate Cancer; Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
- Interventions: Carboplatin; 177Lu-PSMA-617
- Enrollment: 37
- Primary outcome: Maximum tolerated dose (MTD) or the Recommended Phase 2 dose (RP2D) of carboplatin administered in combination with 177Lu-PSMA-617

## Indexed commentary on LuCarbo so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lucarbo-nct06303713